Abatacept in the treatment of rheumatoid arthritis

Arthritis Research and Therapy

Volumn 10, Issue SUPPL. 1, 2008, Pages

  Buch, Maya H ^a   Vital, Edward M ^a   Emery, Paul ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; B7 ANTIGEN; BELATACEPT; CD28 ANTIGEN; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PLACEBO; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIBODY CONJUGATE; ANTIRHEUMATIC AGENT;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE ACTIVITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TARGETING; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; HUMAN; HYPOTENSION; INHIBITION KINETICS; MEDICAL RESEARCH; MELANOMA; MONOTHERAPY; PATHOGENESIS; PNEUMONIA; PSORIASIS; QUALITY OF LIFE; RASH; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; THORAX PAIN; TREATMENT OUTCOME; VASCULITIS; IMMUNOLOGY;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; IMMUNOCONJUGATES; T-LYMPHOCYTES;

EID: 54049120250     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2416     Document Type: Review

References (49)

1. Calin A Elswood J Klouda PT Destructive arthritis, rheumatoid factor, and HLA-DR4. Susceptibility versus severity, a case-control study Arthritis Rheum 1989, 32:1221-1225.
2. Winchester R The molecular basis of susceptibility to rheumatoid arthritis Adv Immunol 1994, 56:389-466.
3. + T cells Cell Immunol 1992, 144:347-357.
4. + T cells and can be amplified by iron Cell Immunol 1989, 121:1-12.
5. Mima T Saeki Y Ohshima S Nishimoto N Matsushita M Shimizu M Kobayashi Y Nomura T Kishimoto T Transfer of rheumatoid arthritis into severe combined immunodeficient mice. The pathogenetic implications of T cell populations oligoclonally expanding in the rheumatoid joints J Clin Invest 1995, 96:1746-1758.
6. Van Boxel JA Paget SA Predominantly T-cell infiltrate in rheumatoid synovial membranes N Engl J Med 1975, 293:517-520.
7. + cytotoxic cells are associated with joint damage in patients with recent onset rheumatoid arthritis Ann Rheum Dis 2004, 63:483-488.
8. Feldmann M Brennan FM Maini RN Role of cytokines in rheumatoid arthritis Annu Rev Immunol 1996, 14:397-440.
9. Maini R St Clair EW Breedveld F Furst D Kalden J Weisman M Smolen J Emery P Harriman G Feldmann M Lipsky P Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. ATTRACT Study Group Lancet 1999, 354:1932-1939.
10. Moreland LW Baumgartner SW Schiff MH Tindall EA Fleischmann RM Weaver AL Ettlinger RE Cohen S Koopman WJ Mohler K Widmer MB Blosch CM Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein N Engl J Med 1997, 337:141-147.
11. Lipsky PE Heijde van der DM St Clair EW Furst DE Breedveld FC Kalden JR Smolen JS Weisman M Emery P Feldmann M Harriman GR Maini RN Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group N Engl J Med 2000, 343:1594-1602.
12. Linsley PS Brady W Urnes M Grosmaire LS Damle NK Ledbetter JA CTLA-4 is a second receptor for the B cell activation antigen B7 J Exp Med 1991, 174:561-569.
13. Alegre ML Frauwirth KA Thompson CB T-cell regulation by CD28 and CTLA-4 Nat Rev Immunol 2001, 1:220-228.
14. Lenschow DJ Zeng Y Thistlethwaite JR Montag A Brady W Gibson MG Linsley PS Bluestone JA Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg Science 1992, 257:789-792.
15. Finck BK Linsley PS Wofsy D Treatment of murine lupus with CTLA4Ig Science 1994, 265:1225-1227.
16. Reynolds J Tam FW Chandraker A Smith J Karkar AM Cross J Peach R Sayegh MH Pusey CD CD28-B7 blockade prevents the development of experimental autoimmune glomerulonephritis J Clin Invest 2000, 105:643-651.
17. Webb LM Walmsley MJ Feldmann M Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: Requirement for both B7-1 and B7-2 Eur J Immunol 1996, 26:2320-2328.
18. Abrams JR Lebwohl MG Guzzo CA Jegasothy BV Goldfarb MT Goffe BS Menter A Lowe NJ Krueger G Brown MJ Weiner RS Birkhofer MJ Warner GL Berry KK Linsley PS Krueger JG Ochs HD Kelley SL Kang S CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris J Clin Invest 1999, 103:1243-1252.
19. Moreland LW Alten R Bosch Van den F Appelboom T Leon M Emery P Cohen S Luggen M Shergy W Nuamah I Becker JC Costimulatory blockade in patients with rheumatoid arthritis: A pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion Arthritis Rheum 2002, 46:1470-1479.
20. Kremer JM Westhovens R Leon M Di Giorgio E Alten R Steinfeld S Russell A Dougados M Emery P Nuamah IF Williams GR Becker JC Hagerty DT Moreland LW Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig N Engl J Med 2003, 349:1907-1915.
21. Kremer JM Dougados M Emery P Durez P Sibilia J Shergy W Steinfeld S Tindall E Becker JC Li T Nuamah IF Aranda R Moreland LW Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: Twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial Arthritis Rheum 2005, 52:2263-2271.
22. Kremer JM Genant HK Moreland LW Russell AS Emery P Abud-Mendoza C Szechinski J Li T Ge Z Becker JC Westhovens R Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: A randomized trial Ann Intern Med 2006, 144:865-876.
23. Kremer JM Genant HK Moreland LW Russell AS Emery P Abud-Mendoza C Szechinski J Li T Teng J Becker JC Westhovens R Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abat-acept and methotrexate Arthritis Rheum 2008, 58:953-963.
24. Heijde van der DM van Riel PL Nuver-Zwart IH Putte van de LB Sulphasalazine versus hydroxychloroquine in rheumatoid arthritis: 3-year follow-up Lancet 1990, 335-539.
25. Genant HK Methods of assessing radiographic change in rheumatoid arthritis Am J Med 1983, 75:35-47.
26. Genant HK Jiang Y Peterfy C Lu Y Redei J Countryman PJ Assessment of rheumatoid arthritis using a modified scoring method on digitized and original radiographs Arthritis Rheum 1998, 41:1583-1590.
27. Genant HK Peterfy CG Westhovens R Becker JC Aranda R Vratsanos G Teng J Kremer JM Abatacept inhibits structural damage progression in rheumatoid arthritis: Results from the long-term extension of the AIM trial Ann Rheum Dis 2007.
28. Schiff M Keiserman M Codding C Songcharoen S Berman A Nayiager S Saldate C Li T Aranda R Becker J-C Lin C Cornet PLN Dougados M Efficacy and safety of abatacept or inflix-imab vs placebo in ATTEST: A phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate Ann Rheum Dis 2008, 67:1096-1103.
29. Genovese MC Becker JC Schiff M Luggen M Sherrer Y Kremer J Birbara C Box J Natarajan K Nuamah I Li T Aranda R Hagerty DT Dougados M Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition N Engl J Med 2005, 353:1114-1123.
30. Genovese MC Schiff M Luggen M Becker JC Aranda R Teng J Li T Schmidely N Le Bars M Dougados M Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-TNF therapy Ann Rheum Dis 2008, 67:547-554.
31. Weinblatt M Schiff M Goldman A Kremer J Luggen M Li T Chen D Becker JC Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: A randomised clinical trial Ann Rheum Dis 2007, 66:228-234.
32. Russell AS Wallenstein GV Li T Martin MC Maclean R Blaisdell B Gajria K Cole JC Becker JC Emery P Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment Ann Rheum Dis 2007, 66:189-194.
33. Westhovens R Cole JC Li T Martin M Maclean R Lin P Blaisdell B Wallenstein GV Aranda R Sherrer Y Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial Rheumatology 2006, 45:1238-1246.
34. Weinblatt M Combe B Covucci A Aranda R Becker JC Keystone E Safety of the selective costimulation modulator abat-acept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study Arthritis Rheum 2006, 54:2807-2816.
35. Hyrich KL Silman AJ Watson KD Symmons DP Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: An update on safety Ann Rheum Dis 2004, 63:1538-1543.
36. Dass S Vital EM Emery P Development of psoriasis after B cell depletion with rituximab Arthritis Rheu 2007, 56:2715-2718.
37. Haggerty HG Abbott MA Reilly TP DeVona DA Gleason CR Tay L Dodge R Aranda R Evaluation of immunogenicity of the T cell costimulation modulator abatacept in patients treated for rheumatoid arthritis J Rheumatol 2007, 34:2365-2373.
38. Sibilia J Westhovens R Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis Clin Exp Rheumatol 2007, 25(suppl 46):S46-S56.
39. Judge TA Tang A Spain LM Deans-Gratiot J Sayegh MH Turka LA The in vivo mechanism of action of CTLA4Ig J Immunol 1996, 156:2294-2299.
40. + T cells J Clin Invest 2003, 112:776-784.
41. Shimoyama Y Nagafuchi H Suzuki N Ochi T Sakane T Synovium infiltrating T cells induce excessive synovial cell function through CD28/B7 pathway in patients with rheumatoid arthritis J Rheumatol 1999, 26:2094-2101.
42. Weisman MH Durez P Hallegua D Aranda R Becker JC Nuamah I Vratsanos G Zhou Y Moreland LW Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis J Rheumatol 2006, 33:2162-2166.
43. Davis PM Nadler SG Stetsko DK Suchard SJ Abatacept modulates human dendritic cell-stimulated T-cell proliferation and effector function independent of IDO induction Clin Immunol 2008, 126:38-47.
44. Buch MH Boyle D Saleem B Rosengren S Reece R Rhodes L Radjenovic A English A Tang H Vratsanos G O'Connor P Firestein GS Emery P Mode of action of abatacept in rheumatoid arthritis patients having failed TNF blockade: A histological, gene expression and dynamic MRI study Arthritis Rheum 2005, 52:S1164.
45. Tak PP Taylor PC Breedveld FC Smeets TJ Daha MR Kluin PM Meinders AE Maini RN Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis Arthritis Rheum 1996, 39:1077-1081.
46. Smeets TJ Kraan MC van Loon ME Tak PP Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue Arthritis Rheum 2003, 48:2155-2162.
47. Buch MH Bingham SJ Seto Y McGonagle D Bejarano V White J Emery P Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockade Arthritis Rheum 2004, 50:725-728.
48. Davidson A Diamond B Wofsy D Daikh D Block and tackle: CTLA4Ig takes on lupus Lupus 2005, 14:197-203.
49. Vincenti F Larsen C Durrbach A Wekerle T Nashan B Blancho G Lang P Grinyo J Halloran PF Solez K Hagerty D Levy E Zhou W Natarajan K Charpentier B Belatacept Study Group Costimulation blockade with belatacept in renal transplantation N Engl J Med 2005, 353:770-781.